U.S. flag An official website of the United States government
  1. Home
  2. Tobacco Products
  3. Tobacco Science & Research
  4. Research
  5. Marketing, FDA Communication, Tobacco Perceptions and Use in Addiction Treatment
  1. Research

Marketing, FDA Communication, Tobacco Perceptions and Use in Addiction Treatment

Principal Investigator: Joseph Guydish

Funding Mechanism: National Institutes of Health- Grant

ID number: 1R01DA036066-01

Award Date: 9/30/2013

Institution: University of California San Francisco

Over four million individuals receive some type of addiction treatment annually; in this vulnerable population, smoking rates are high (67-75%) and resistant to tobacco control efforts. Because these individuals are highly likely to smoke, they are also likely to try, use, and adopt emerging and potentially modified risk tobacco products (e.g., e-cigarettes, snus, and smokeless tobacco). Working in collaboration with the National Institute on Drug Abuse (NIDA) Clinical Trials Network, investigators will identify a national random sample of 25 addiction treatment programs where 3,000 patients (1,000 patients per year for three years) plus 25 program directors will be recruited; using web-based computer-assisted strategies, participants will be interviewed concerning use of traditional and emerging tobacco products, exposure to federal tobacco education efforts and industry marketing campaigns, risk perceptions related to a range of tobacco products, and tobacco use behavior. Project goals are to understand tobacco product use, marketing, messaging, and perceptions in addiction treatment populations, and to inform regulatory activities that reduce tobacco use and risks in this vulnerable population. Specific aims are: (1) to assess the prevalence, and changes in prevalence over time, of smoking and use of alternative tobacco products in this population; (2) to assess exposure, and changes in exposure over time, to FDA tobacco-related communications, the role of the FDA, and tobacco marketing, and to examine the relationship of these exposures to risk perceptions regarding tobacco products and their use; and (3) to assess relationships between exposure to FDA communications, tobacco marketing, and perceived tobacco risk and health services measures (tobacco-related attitudes and utilization of tobacco cessation services) and tobacco behavior outcomes (prevalence, quit attempts, cigarettes per day).

Related Resources

Back to Top